| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Gencurix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,315.00 |
| 52 Week High | ₩8,500.00 |
| 52 Week Low | ₩2,100.00 |
| Beta | 0.11 |
| 11 Month Change | -9.57% |
| 3 Month Change | -3.94% |
| 1 Year Change | -52.95% |
| 33 Year Change | -87.07% |
| 5 Year Change | -82.92% |
| Change since IPO | -85.39% |
Recent News & Updates
Shareholder Returns
| A229000 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 3.3% | -3.1% | -1.2% |
| 1Y | -52.9% | 15.3% | 4.8% |
Return vs Industry: A229000 underperformed the KR Medical Equipment industry which returned 15.3% over the past year.
Return vs Market: A229000 underperformed the KR Market which returned 4.8% over the past year.
Price Volatility
| A229000 volatility | |
|---|---|
| A229000 Average Weekly Movement | 13.9% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A229000's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A229000's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 69 | Sung-Rai Cho | www.gencurix.com |
Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.
Gencurix Inc. Fundamentals Summary
| A229000 fundamental statistics | |
|---|---|
| Market cap | ₩35.29b |
| Earnings (TTM) | -₩14.25b |
| Revenue (TTM) | ₩2.91b |
12.1x
P/S Ratio-2.5x
P/E RatioIs A229000 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A229000 income statement (TTM) | |
|---|---|
| Revenue | ₩2.91b |
| Cost of Revenue | ₩1.20b |
| Gross Profit | ₩1.71b |
| Other Expenses | ₩15.96b |
| Earnings | -₩14.25b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -934.59 |
| Gross Margin | 58.76% |
| Net Profit Margin | -488.85% |
| Debt/Equity Ratio | 124.1% |
How did A229000 perform over the long term?
See historical performance and comparison